Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Buy
70
VNDA Quote, Financials, Valuation and Earnings
Last price:
$6.85
Seasonality move
:
-3.34%
Day range:
$6.79 - $7.18
52-week range:
$3.81 - $7.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.89x
P/B ratio:
0.87x
Volume:
1.5M
Avg. volume:
1.3M
1-year change:
46.15%
Market cap:
$404.2M
Revenue:
$198.8M
EPS (TTM):
-$1.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$58.7M | -- | 11.45% | -- | $11.75 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.96% | -83.59% | $29.79 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-- | -$0.16 | -- | -44.74% | $9.67 |
|
ANAB
AnaptysBio, Inc.
|
$21.8M | -$1.25 | 102.4% | -12.82% | $65.09 |
|
EXEL
Exelixis, Inc.
|
$590.2M | $0.67 | 7.5% | 59.24% | $45.28 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$6.84 | $11.75 | $404.2M | -- | $0.00 | 0% | 1.89x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.83 | $29.79 | $4.7B | 17.91x | $0.00 | 0% | 4.48x |
|
ADMA
ADMA Biologics, Inc.
|
$19.50 | $25.67 | $4.6B | 22.89x | $0.00 | 0% | 9.81x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.05 | $9.67 | $303.5M | -- | $0.00 | 0% | -- |
|
ANAB
AnaptysBio, Inc.
|
$50.07 | $65.09 | $1.4B | -- | $0.00 | 0% | 8.78x |
|
EXEL
Exelixis, Inc.
|
$46.61 | $45.28 | $12.5B | 19.62x | $0.00 | 0% | 5.83x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 1.936 | 4.95% | 2.64x |
|
ANAB
AnaptysBio, Inc.
|
109.28% | 2.106 | 41.03% | 8.52x |
|
EXEL
Exelixis, Inc.
|
7.55% | 0.460 | 1.59% | 3.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
ANAB
AnaptysBio, Inc.
|
$75.7M | $34.7M | -22.38% | -367.62% | 45.47% | -$27.4M |
|
EXEL
Exelixis, Inc.
|
$579.2M | $256.4M | 28.73% | 31.26% | 42.89% | $288.8M |
Vanda Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns VNDA or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 25.76%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About VNDA or ACAD?
Vanda Pharmaceuticals, Inc. has a consensus price target of $11.75, signalling upside risk potential of 71.78%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.79 which suggests that it could grow by 6.16%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is VNDA or ACAD More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.687, which suggesting that the stock is 31.308% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock VNDA or ACAD?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ACAD?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.89x versus 4.48x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.89x -- $56.3M -$22.6M ACADACADIA Pharmaceuticals, Inc.4.48x 17.91x $278.6M $71.8M
-
Which has Higher Returns VNDA or ADMA?
ADMA Biologics, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 27.14%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About VNDA or ADMA?
Vanda Pharmaceuticals, Inc. has a consensus price target of $11.75, signalling upside risk potential of 71.78%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 29.11%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is VNDA or ADMA More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.687, which suggesting that the stock is 31.308% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock VNDA or ADMA?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ADMA?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.89x versus 9.81x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.89x -- $56.3M -$22.6M ADMAADMA Biologics, Inc.9.81x 22.89x $134.2M $36.4M
-
Which has Higher Returns VNDA or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of --. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About VNDA or ALDX?
Vanda Pharmaceuticals, Inc. has a consensus price target of $11.75, signalling upside risk potential of 71.78%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 74.49%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ALDXAldeyra Therapeutics, Inc.4 0 0 -
Is VNDA or ALDX More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.687, which suggesting that the stock is 31.308% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.
-
Which is a Better Dividend Stock VNDA or ALDX?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ALDX?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.89x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.89x -- $56.3M -$22.6M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns VNDA or ANAB?
AnaptysBio, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 19.8%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat AnaptysBio, Inc.'s return on equity of -367.62%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M ANABAnaptysBio, Inc.99.2% $0.52 $317M -
What do Analysts Say About VNDA or ANAB?
Vanda Pharmaceuticals, Inc. has a consensus price target of $11.75, signalling upside risk potential of 71.78%. On the other hand AnaptysBio, Inc. has an analysts' consensus of $65.09 which suggests that it could grow by 29.33%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ANABAnaptysBio, Inc.8 1 0 -
Is VNDA or ANAB More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.687, which suggesting that the stock is 31.308% less volatile than S&P 500. In comparison AnaptysBio, Inc. has a beta of 0.286, suggesting its less volatile than the S&P 500 by 71.412%.
-
Which is a Better Dividend Stock VNDA or ANAB?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnaptysBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AnaptysBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ANAB?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than AnaptysBio, Inc. quarterly revenues of $76.3M. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than AnaptysBio, Inc.'s net income of $15.1M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AnaptysBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.89x versus 8.78x for AnaptysBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.89x -- $56.3M -$22.6M ANABAnaptysBio, Inc.8.78x -- $76.3M $15.1M
-
Which has Higher Returns VNDA or EXEL?
Exelixis, Inc. has a net margin of -40.15% compared to Vanda Pharmaceuticals, Inc.'s net margin of 32.38%. Vanda Pharmaceuticals, Inc.'s return on equity of -16.55% beat Exelixis, Inc.'s return on equity of 31.26%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M EXELExelixis, Inc.96.89% $0.70 $2.3B -
What do Analysts Say About VNDA or EXEL?
Vanda Pharmaceuticals, Inc. has a consensus price target of $11.75, signalling upside risk potential of 71.78%. On the other hand Exelixis, Inc. has an analysts' consensus of $45.28 which suggests that it could fall by -2.86%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Exelixis, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Exelixis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 EXELExelixis, Inc.9 9 0 -
Is VNDA or EXEL More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.687, which suggesting that the stock is 31.308% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.
-
Which is a Better Dividend Stock VNDA or EXEL?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or EXEL?
Vanda Pharmaceuticals, Inc. quarterly revenues are $56.3M, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Vanda Pharmaceuticals, Inc.'s net income of -$22.6M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 19.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.89x versus 5.83x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.89x -- $56.3M -$22.6M EXELExelixis, Inc.5.83x 19.62x $597.8M $193.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 3.24% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 1.39% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.1% over the past day.
